Amedisys (Nasdaq: AMED ) is expected to report Q3 earnings on Nov. 6. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Amedisys's revenues will grow 1.4% and EPS will shrink -25.0%.
The average estimate for revenue is $380.0 million. On the bottom line, the average EPS estimate is $0.27.
Last quarter, Amedisys reported revenue of $378.5 million. GAAP reported sales were 2.7% higher than the prior-year quarter's $368.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.27. GAAP EPS of $0.26 for Q2 were 65% lower than the prior-year quarter's $0.75 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 43.9%, 470 basis points worse than the prior-year quarter. Operating margin was 4.1%, 680 basis points worse than the prior-year quarter. Net margin was 2.1%, 380 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $1.51 billion. The average EPS estimate is $1.01.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 815 members out of 907 rating the stock outperform, and 92 members rating it underperform. Among 214 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 183 give Amedisys a green thumbs-up, and 31 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Amedisys is hold, with an average price target of $12.61.